Entera Bio Ltd. Accounts Payable

Accounts Payable of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Accounts Payable growth rates and interactive chart. Accounts payable (AP) represents a company's obligation to pay off a short-term debt to its creditors or suppliers. Accounts payable are amounts due to vendors or suppliers for goods or services received that have not yet been paid for. The sum of all outstanding amounts owed to vendors is shown as the accounts payable balance on the company's balance sheet. The increase or decrease in total AP from the prior period appears on the cash flow statement.


Highlights and Quick Summary

  • Accounts Payable for the quarter ending June 29, 2020 was $49 Thousand (a -88.63% decrease compared to previous quarter)
  • Year-over-year quarterly Accounts Payable decreased by -91.75%
  • Annual Accounts Payable for 2019 was $334 Thousand (a -29.39% decrease from previous year)
  • Annual Accounts Payable for 2018 was $473 Thousand (a -20.64% decrease from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Accounts Payable of Entera Bio Ltd.

Most recent Accounts Payableof ENTX including historical data for past 10 years.

Interactive Chart of Accounts Payable of Entera Bio Ltd.

Entera Bio Ltd. Accounts Payable for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.05 $0.43
2019 $0.33 $0.59 $0.49 $0.8 $0.33
2018 $0.47 $0.47
2017 $0.6 $0.6

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.